Untitled chapter

The lever is N-N-M-T — nicotinamide N-methyltransferase. N-N-M-T chews through methyl donors and degrades nicotinamide on the way to N-A-D plus. In insulin-resistant tissue, N-N-M-T is upregulated. The cell has the precursors. The cell wastes them. N-A-D plus stays low. Sirtuins stay quiet. A-M-P-K stays sluggish. Fatty acid oxidation defaults to storage instead of burn. The substrate framing is direct: N-M-N raises N-A-D plus supply; 5-Amino-1MQ cuts N-A-D plus waste. Running both creates a net positive N-A-D plus balance that neither achieves alone — and 5-Amino-1MQ does the heavier lift in a metabolic-syndrome physiology where N-N-M-T is already overexpressed. [short pause] Mechanistically, blocking N-N-M-T does two things at once. First, it preserves the METHYL DONOR POOL — S-adenosylmethionine stops getting drained into N-methylnicotinamide, freeing methylation capacity for everything downstream: catechol clearance, D-N-A repair, phosphatidylcholine synthesis. Second, it restores the N-A-D plus salvage cycle inside adipocytes and skeletal muscle, which flips lipolysis back on. The clinical fingerprint matches what the practitioner corpus reports: stubborn fat — particularly visceral and lower-body subcutaneous — that wouldn't move on G-L-P 1 alone starts moving in Weeks six through eight. [short pause] The COMPLIANCE QUESTION is the real failure point. Adding an oral compound to an existing injectable schedule is where Phase 2 plans collapse. Two specific failure modes show up in the corpus. The first is G-I overlap: G-L-P 1 agonists already slow gastric emptying, and introducing an oral peptide on top of a nausea-baseline can wreck adherence inside seventy-two hours. The second is dose timing — 5-Amino-1MQ has a roughly six to eight hour active window on lipolysis signaling, so a single morning dose underdelivers. The fix is SPLIT DOSING, anchored away from the G-L-P 1 trough. [short pause] Here is the Phase 2 stack for Weeks five through ten. First, 5-Amino-1MQ, expert tier, dosed at fifty to one hundred milligrams per day orally, split between morning and early afternoon. Start at fifty milligrams morning-only in Week 5. Add another fifty milligrams in the early afternoon in Week 6 if G-I tolerant. This is a cycled compound — the schedule is covered in the maintenance chapter. Next, Tirzepatide continued from Phase 1, clinical tier, subcutaneous weekly — hold the Week 4 dose and do not titrate up. Pause titration during 5-Amino-1MQ introduction. Resume titration only after two weeks of stable G-I on the combined stack. Then MOTS-c, expert tier, five to ten milligrams per week total subcutaneous, split Monday and Thursday — this is an optional Week 7 add-in for the A-M-P-K layer. Skip it if fasting insulin is still above eight micro-international-units per milliliter; get insulin under eight first. Berberine continues from Phase 1, expert tier, five hundred milligrams two to three times daily, totaling one thousand to one thousand five hundred milligrams per day, oral with meals. Take with the largest meals. Do not drop at the Phase 2 transition. Cycle three months on, one month off. Methylene Blue, experimental tier, point five to one milligram per day, oral in the morning — pharmaceutical-grade only. The ten to fifteen milligram doses circulated online flip the dose-response curve from beneficial to harmful. Cycle four to six weeks on, two to four weeks off. And finally N-M-N, experimental tier, oral, morning fasted. The practitioner corpus is thin on the exact Phase 2 dose — most references frame it as two hundred fifty to five hundred milligrams per day morning fasted; track and report. It pairs N-A-D plus supply with 5-Amino-1MQ's waste-reduction side. [short pause] Pharmacokinetic overlap data between Tirzepatide and 5-Amino-1MQ specifically is not in the corpus. The practitioner corpus is thin on co-administration timing — track G-I and report. Default protocol is to take the morning 5-Amino-1MQ dose at least four hours after the Tirzepatide injection morning, ideally on a non-injection day for the first week of the layered stack. [short pause] One rule the substrate is loud on: if fasting insulin is still above eight micro-international-units per milliliter going into Week 5, do NOT add G-H secretagogues — Ipamorelin, CJC-1295, Tesamorelin — to the Phase 2 stack. Growth hormone antagonizes insulin at the receptor level. Layering G-H on unresolved hyperinsulinemia pushes the cell deeper into metabolic dysfunction — the opposite of what Phase 2 is for. Resolve insulin first; G-H axis work is a Phase 3 conversation, and the Blood Sugar Path is deliberately not running it. [short pause] What you should feel across Weeks five through ten. In Week 5, expect a mild thermogenic uptick sixty to ninety minutes after the morning 5-Amino-1MQ dose. Clean alertness, no cortisol spike. No appetite change yet — that's still the G-L-P 1's domain. In Week 6, stubborn-fat sites — lower abdomen, hip and thigh in some morphologies — feel softer to palpation before visible measurement change. Waist often drops half an inch to one inch. In Weeks 7 and 8, visible recomposition begins. Energy is the second-stage signal: workouts that felt aerobic-capped in Phase 1 unlock another gear because fatty acid oxidation is producing usable A-T-P again. In Weeks 9 and 10, fasting insulin should be moving below six micro-international-units per milliliter. HOMA-I-R drops accordingly. If it's not moving, Phase 2 is doing the wrong job for your physiology — the next chapter covers the branch logic. [short pause] And what is NOT happening yet. No new appetite suppression — that was Phase 1's gift. 5-Amino-1MQ does not blunt appetite; if hunger returns, it's the G-L-P 1 dose, not the new compound. No D-E-X-A-meaningful muscle gain. Phase 2 is a metabolic flexibility layer, not an anabolic one. Protein intake at one point six grams per kilogram lean mass or higher remains the muscle-preservation lever; the compounds do not substitute. No A1c collapse week-to-week. A1c is a ninety-day rolling average. The Week 10 draw will show Phase 2's contribution; the Week 6 draw will not. No "fat just falls off" pattern. 5-Amino-1MQ shifts the gradient — it does not override caloric reality. Resistance training and protein-anchored meals still do most of the work. No G-H axis benefit. Sleep architecture, I-G-F 1 trajectory, deep recovery — Phase 2 doesn't touch those. They belong to a different protocol on a different physiology. And no paradoxical fatigue. If brain fog or muscle weakness appears in Week 5 or 6, the mitochondria are inflamed beyond the A-M-P-K push's tolerance. Reduce the 5-Amino-1MQ dose to fifty milligrams morning-only and support with CoQ10 and B-complex before re-layering. [short pause] Research describes this layered pattern. Track fasting insulin, waist measurement, and G-I tolerance weekly. Adjust.